Company intelligence / Profile preview

Theragent

Arcadia, California, United Statestheragent.com ↗

Ownership: Private
Development stage: Phase 2

Overview

Theragent has successfully supported the manufacture of autologous cancer vaccines for Phase 2 trials in partnership with CellVax Therapeutics. The company’s state-of-the-art facility enables end-to-end cGMP-compliant production of advanced cell and gene therapies from early development through commercialization.

Therapeutic areas: OncologyRare DiseasesOther
Modalities: Cell therapyGene therapyViral vector-based therapyStem cell therapy (including iPSC-derived therapies)NK cell therapyT-cell therapy
Industry: Contract Manufacturing Organization

Drug pipeline

1 asset

FK-PC101

Phase 2

Indications: Prostate cancer

Partnerships

Pluristyx Inc. — partnership to streamline iPSC-derived therapeutic development using Pluristyx’s panCELLa platform technologies combined with Theragent’s GMP manufacturing capabilities.

Beyond the preview

Go deeper on Theragent.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theragent.